nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ALB—Crohn's disease	0.4	1	CbGaD
Tacrolimus—CYP3A5—Sulfasalazine—Crohn's disease	0.0402	0.354	CbGbCtD
Tacrolimus—ALB—Prednisone—Crohn's disease	0.04	0.352	CbGbCtD
Tacrolimus—ABCB1—Prednisone—Crohn's disease	0.0209	0.184	CbGbCtD
Tacrolimus—ORM1—bile—Crohn's disease	0.014	0.175	CbGeAlD
Tacrolimus—CYP3A4—Prednisone—Crohn's disease	0.0125	0.11	CbGbCtD
Tacrolimus—ABCA5—mammalian vulva—Crohn's disease	0.00496	0.062	CbGeAlD
Tacrolimus—ORM1—gall bladder—Crohn's disease	0.00388	0.0486	CbGeAlD
Tacrolimus—PPP3CA—smooth muscle tissue—Crohn's disease	0.00372	0.0466	CbGeAlD
Tacrolimus—ALB—gall bladder—Crohn's disease	0.00341	0.0426	CbGeAlD
Tacrolimus—PPP3CA—mammalian vulva—Crohn's disease	0.00335	0.0419	CbGeAlD
Tacrolimus—PPP3CA—lymphoid tissue—Crohn's disease	0.00297	0.0372	CbGeAlD
Tacrolimus—PPP3CA—digestive system—Crohn's disease	0.00294	0.0368	CbGeAlD
Tacrolimus—MTOR—epithelium—Crohn's disease	0.00285	0.0357	CbGeAlD
Tacrolimus—MTOR—smooth muscle tissue—Crohn's disease	0.00275	0.0344	CbGeAlD
Tacrolimus—MTOR—skin of body—Crohn's disease	0.00271	0.0339	CbGeAlD
Tacrolimus—FKBP1A—epithelium—Crohn's disease	0.00257	0.0321	CbGeAlD
Tacrolimus—ABCA5—lymph node—Crohn's disease	0.00248	0.0311	CbGeAlD
Tacrolimus—MTOR—mammalian vulva—Crohn's disease	0.00248	0.031	CbGeAlD
Tacrolimus—FKBP1A—smooth muscle tissue—Crohn's disease	0.00247	0.0309	CbGeAlD
Tacrolimus—FKBP1A—skin of body—Crohn's disease	0.00244	0.0305	CbGeAlD
Tacrolimus—FKBP1A—mammalian vulva—Crohn's disease	0.00223	0.0278	CbGeAlD
Tacrolimus—MTOR—lymphoid tissue—Crohn's disease	0.0022	0.0275	CbGeAlD
Tacrolimus—MTOR—digestive system—Crohn's disease	0.00217	0.0271	CbGeAlD
Tacrolimus—FKBP1A—lymphoid tissue—Crohn's disease	0.00198	0.0247	CbGeAlD
Tacrolimus—FKBP1A—digestive system—Crohn's disease	0.00195	0.0244	CbGeAlD
Tacrolimus—PPP3CA—lymph node—Crohn's disease	0.00168	0.021	CbGeAlD
Tacrolimus—MTOR—lymph node—Crohn's disease	0.00124	0.0155	CbGeAlD
Tacrolimus—FKBP1A—lymph node—Crohn's disease	0.00112	0.0139	CbGeAlD
Tacrolimus—ORM1—lymph node—Crohn's disease	0.000873	0.0109	CbGeAlD
Tacrolimus—CYP3A5—digestive system—Crohn's disease	0.00085	0.0106	CbGeAlD
Tacrolimus—ALB—lymph node—Crohn's disease	0.000766	0.00958	CbGeAlD
Tacrolimus—CYP3A4—digestive system—Crohn's disease	0.000638	0.00798	CbGeAlD
Tacrolimus—ABCB1—epithelium—Crohn's disease	0.000594	0.00742	CbGeAlD
Tacrolimus—ABCB1—mammalian vulva—Crohn's disease	0.000515	0.00644	CbGeAlD
Tacrolimus—ABCB1—lymphoid tissue—Crohn's disease	0.000457	0.00572	CbGeAlD
Tacrolimus—ABCB1—digestive system—Crohn's disease	0.000452	0.00565	CbGeAlD
Tacrolimus—Neutropenia—Mesalazine—Crohn's disease	0.000398	0.00135	CcSEcCtD
Tacrolimus—Arthropathy—Prednisone—Crohn's disease	0.000394	0.00134	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Azathioprine—Crohn's disease	0.000394	0.00134	CcSEcCtD
Tacrolimus—Pollakiuria—Mesalazine—Crohn's disease	0.000393	0.00134	CcSEcCtD
Tacrolimus—Agranulocytosis—Azathioprine—Crohn's disease	0.000388	0.00132	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Mesalazine—Crohn's disease	0.000388	0.00132	CcSEcCtD
Tacrolimus—Decreased appetite—Mercaptopurine—Crohn's disease	0.000387	0.00132	CcSEcCtD
Tacrolimus—Weight increased—Mesalazine—Crohn's disease	0.000387	0.00132	CcSEcCtD
Tacrolimus—Weight decreased—Mesalazine—Crohn's disease	0.000385	0.00131	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000385	0.00131	CcSEcCtD
Tacrolimus—Leukocytosis—Prednisone—Crohn's disease	0.000381	0.0013	CcSEcCtD
Tacrolimus—Pneumonia—Mesalazine—Crohn's disease	0.000381	0.0013	CcSEcCtD
Tacrolimus—Infestation NOS—Mesalazine—Crohn's disease	0.000379	0.00129	CcSEcCtD
Tacrolimus—Infestation—Mesalazine—Crohn's disease	0.000379	0.00129	CcSEcCtD
Tacrolimus—Ulcer—Prednisone—Crohn's disease	0.000379	0.00129	CcSEcCtD
Tacrolimus—Hypercholesterolaemia—Prednisone—Crohn's disease	0.000379	0.00129	CcSEcCtD
Tacrolimus—Depression—Mesalazine—Crohn's disease	0.000378	0.00129	CcSEcCtD
Tacrolimus—Cataract—Prednisone—Crohn's disease	0.000377	0.00128	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.000376	0.00128	CcSEcCtD
Tacrolimus—Haemoglobin—Azathioprine—Crohn's disease	0.000375	0.00128	CcSEcCtD
Tacrolimus—Haemorrhage—Azathioprine—Crohn's disease	0.000374	0.00127	CcSEcCtD
Tacrolimus—Renal failure—Mesalazine—Crohn's disease	0.000373	0.00127	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Mesalazine—Crohn's disease	0.000372	0.00127	CcSEcCtD
Tacrolimus—Jaundice—Mesalazine—Crohn's disease	0.000369	0.00126	CcSEcCtD
Tacrolimus—Stomatitis—Mesalazine—Crohn's disease	0.000369	0.00126	CcSEcCtD
Tacrolimus—Urinary tract infection—Mesalazine—Crohn's disease	0.000368	0.00125	CcSEcCtD
Tacrolimus—Conjunctivitis—Mesalazine—Crohn's disease	0.000368	0.00125	CcSEcCtD
Tacrolimus—Sweating—Mesalazine—Crohn's disease	0.000363	0.00124	CcSEcCtD
Tacrolimus—Haematuria—Mesalazine—Crohn's disease	0.000361	0.00123	CcSEcCtD
Tacrolimus—Hiccups—Prednisone—Crohn's disease	0.000359	0.00122	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Mesalazine—Crohn's disease	0.000359	0.00122	CcSEcCtD
Tacrolimus—Epistaxis—Mesalazine—Crohn's disease	0.000358	0.00122	CcSEcCtD
Tacrolimus—Sinusitis—Mesalazine—Crohn's disease	0.000356	0.00121	CcSEcCtD
Tacrolimus—Agranulocytosis—Mesalazine—Crohn's disease	0.000354	0.0012	CcSEcCtD
Tacrolimus—Erythema multiforme—Azathioprine—Crohn's disease	0.000353	0.0012	CcSEcCtD
Tacrolimus—Body temperature increased—Mercaptopurine—Crohn's disease	0.000352	0.0012	CcSEcCtD
Tacrolimus—Haemoglobin—Mesalazine—Crohn's disease	0.000342	0.00116	CcSEcCtD
Tacrolimus—Rhinitis—Mesalazine—Crohn's disease	0.000341	0.00116	CcSEcCtD
Tacrolimus—Fluid retention—Prednisone—Crohn's disease	0.00034	0.00116	CcSEcCtD
Tacrolimus—Hepatitis—Mesalazine—Crohn's disease	0.00034	0.00116	CcSEcCtD
Tacrolimus—Haemorrhage—Mesalazine—Crohn's disease	0.00034	0.00116	CcSEcCtD
Tacrolimus—Pharyngitis—Mesalazine—Crohn's disease	0.000338	0.00115	CcSEcCtD
Tacrolimus—Immune system disorder—Azathioprine—Crohn's disease	0.000337	0.00115	CcSEcCtD
Tacrolimus—Mediastinal disorder—Azathioprine—Crohn's disease	0.000337	0.00115	CcSEcCtD
Tacrolimus—Neuropathy—Prednisone—Crohn's disease	0.000337	0.00115	CcSEcCtD
Tacrolimus—Urinary tract disorder—Mesalazine—Crohn's disease	0.000336	0.00114	CcSEcCtD
Tacrolimus—Oedema peripheral—Mesalazine—Crohn's disease	0.000335	0.00114	CcSEcCtD
Tacrolimus—Chills—Azathioprine—Crohn's disease	0.000335	0.00114	CcSEcCtD
Tacrolimus—Connective tissue disorder—Mesalazine—Crohn's disease	0.000334	0.00114	CcSEcCtD
Tacrolimus—Arrhythmia—Azathioprine—Crohn's disease	0.000334	0.00114	CcSEcCtD
Tacrolimus—Urethral disorder—Mesalazine—Crohn's disease	0.000334	0.00114	CcSEcCtD
Tacrolimus—Alopecia—Azathioprine—Crohn's disease	0.00033	0.00112	CcSEcCtD
Tacrolimus—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000328	0.00112	CcSEcCtD
Tacrolimus—Oesophagitis—Prednisone—Crohn's disease	0.000328	0.00112	CcSEcCtD
Tacrolimus—Ecchymosis—Prednisone—Crohn's disease	0.000324	0.0011	CcSEcCtD
Tacrolimus—Erythema multiforme—Mesalazine—Crohn's disease	0.000322	0.0011	CcSEcCtD
Tacrolimus—Pulmonary oedema—Prednisone—Crohn's disease	0.000319	0.00109	CcSEcCtD
Tacrolimus—Eye disorder—Mesalazine—Crohn's disease	0.000318	0.00108	CcSEcCtD
Tacrolimus—Tinnitus—Mesalazine—Crohn's disease	0.000317	0.00108	CcSEcCtD
Tacrolimus—Cardiac disorder—Mesalazine—Crohn's disease	0.000316	0.00108	CcSEcCtD
Tacrolimus—Sepsis—Prednisone—Crohn's disease	0.000311	0.00106	CcSEcCtD
Tacrolimus—Angiopathy—Mesalazine—Crohn's disease	0.000309	0.00105	CcSEcCtD
Tacrolimus—Immune system disorder—Mesalazine—Crohn's disease	0.000307	0.00105	CcSEcCtD
Tacrolimus—Mediastinal disorder—Mesalazine—Crohn's disease	0.000307	0.00104	CcSEcCtD
Tacrolimus—Chills—Mesalazine—Crohn's disease	0.000305	0.00104	CcSEcCtD
Tacrolimus—Diarrhoea—Mercaptopurine—Crohn's disease	0.000305	0.00104	CcSEcCtD
Tacrolimus—Ill-defined disorder—Azathioprine—Crohn's disease	0.000302	0.00103	CcSEcCtD
Tacrolimus—Alopecia—Mesalazine—Crohn's disease	0.000301	0.00102	CcSEcCtD
Tacrolimus—Thrombophlebitis—Prednisone—Crohn's disease	0.000301	0.00102	CcSEcCtD
Tacrolimus—Anaemia—Azathioprine—Crohn's disease	0.000301	0.00102	CcSEcCtD
Tacrolimus—Diabetes mellitus—Prednisone—Crohn's disease	0.000299	0.00102	CcSEcCtD
Tacrolimus—Mental disorder—Mesalazine—Crohn's disease	0.000298	0.00102	CcSEcCtD
Tacrolimus—Erythema—Mesalazine—Crohn's disease	0.000296	0.00101	CcSEcCtD
Tacrolimus—Malaise—Azathioprine—Crohn's disease	0.000293	0.000999	CcSEcCtD
Tacrolimus—Flatulence—Mesalazine—Crohn's disease	0.000292	0.000994	CcSEcCtD
Tacrolimus—Leukopenia—Azathioprine—Crohn's disease	0.000291	0.000991	CcSEcCtD
Tacrolimus—Tension—Mesalazine—Crohn's disease	0.000291	0.00099	CcSEcCtD
Tacrolimus—Dysgeusia—Mesalazine—Crohn's disease	0.00029	0.000988	CcSEcCtD
Tacrolimus—Nervousness—Mesalazine—Crohn's disease	0.000288	0.00098	CcSEcCtD
Tacrolimus—Cardiac failure congestive—Prednisone—Crohn's disease	0.000287	0.000977	CcSEcCtD
Tacrolimus—Back pain—Mesalazine—Crohn's disease	0.000287	0.000976	CcSEcCtD
Tacrolimus—Muscle spasms—Mesalazine—Crohn's disease	0.000285	0.00097	CcSEcCtD
Tacrolimus—Vomiting—Mercaptopurine—Crohn's disease	0.000283	0.000964	CcSEcCtD
Tacrolimus—Injury—Prednisone—Crohn's disease	0.000283	0.000964	CcSEcCtD
Tacrolimus—Rash—Mercaptopurine—Crohn's disease	0.000281	0.000956	CcSEcCtD
Tacrolimus—Dermatitis—Mercaptopurine—Crohn's disease	0.000281	0.000955	CcSEcCtD
Tacrolimus—Vision blurred—Mesalazine—Crohn's disease	0.000279	0.000951	CcSEcCtD
Tacrolimus—Tremor—Mesalazine—Crohn's disease	0.000278	0.000945	CcSEcCtD
Tacrolimus—Increased appetite—Prednisone—Crohn's disease	0.000277	0.000943	CcSEcCtD
Tacrolimus—Amnesia—Prednisone—Crohn's disease	0.000277	0.000943	CcSEcCtD
Tacrolimus—Myalgia—Azathioprine—Crohn's disease	0.000277	0.000943	CcSEcCtD
Tacrolimus—Arthralgia—Azathioprine—Crohn's disease	0.000277	0.000943	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000275	0.000936	CcSEcCtD
Tacrolimus—Ill-defined disorder—Mesalazine—Crohn's disease	0.000275	0.000936	CcSEcCtD
Tacrolimus—Anaemia—Mesalazine—Crohn's disease	0.000274	0.000932	CcSEcCtD
Tacrolimus—Discomfort—Azathioprine—Crohn's disease	0.000274	0.000931	CcSEcCtD
Tacrolimus—Malaise—Mesalazine—Crohn's disease	0.000267	0.00091	CcSEcCtD
Tacrolimus—Cardiac failure—Prednisone—Crohn's disease	0.000267	0.000908	CcSEcCtD
Tacrolimus—Vertigo—Mesalazine—Crohn's disease	0.000266	0.000906	CcSEcCtD
Tacrolimus—Syncope—Mesalazine—Crohn's disease	0.000266	0.000904	CcSEcCtD
Tacrolimus—Leukopenia—Mesalazine—Crohn's disease	0.000265	0.000903	CcSEcCtD
Tacrolimus—Nausea—Mercaptopurine—Crohn's disease	0.000265	0.000901	CcSEcCtD
Tacrolimus—Infection—Azathioprine—Crohn's disease	0.000264	0.000898	CcSEcCtD
Tacrolimus—Palpitations—Mesalazine—Crohn's disease	0.000262	0.000891	CcSEcCtD
Tacrolimus—Loss of consciousness—Mesalazine—Crohn's disease	0.00026	0.000886	CcSEcCtD
Tacrolimus—Osteoarthritis—Prednisone—Crohn's disease	0.00026	0.000886	CcSEcCtD
Tacrolimus—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.00026	0.000886	CcSEcCtD
Tacrolimus—Thrombocytopenia—Azathioprine—Crohn's disease	0.00026	0.000885	CcSEcCtD
Tacrolimus—Cough—Mesalazine—Crohn's disease	0.000258	0.00088	CcSEcCtD
Tacrolimus—ABCB1—lymph node—Crohn's disease	0.000258	0.00323	CbGeAlD
Tacrolimus—Skin disorder—Azathioprine—Crohn's disease	0.000258	0.000878	CcSEcCtD
Tacrolimus—Affect lability—Prednisone—Crohn's disease	0.000256	0.000872	CcSEcCtD
Tacrolimus—Hypertension—Mesalazine—Crohn's disease	0.000256	0.000871	CcSEcCtD
Tacrolimus—Psychotic disorder—Prednisone—Crohn's disease	0.000254	0.000865	CcSEcCtD
Tacrolimus—Arthralgia—Mesalazine—Crohn's disease	0.000252	0.000859	CcSEcCtD
Tacrolimus—Chest pain—Mesalazine—Crohn's disease	0.000252	0.000859	CcSEcCtD
Tacrolimus—Myalgia—Mesalazine—Crohn's disease	0.000252	0.000859	CcSEcCtD
Tacrolimus—Anxiety—Mesalazine—Crohn's disease	0.000251	0.000856	CcSEcCtD
Tacrolimus—Face oedema—Prednisone—Crohn's disease	0.000251	0.000855	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.00025	0.000853	CcSEcCtD
Tacrolimus—Discomfort—Mesalazine—Crohn's disease	0.000249	0.000848	CcSEcCtD
Tacrolimus—Hypotension—Azathioprine—Crohn's disease	0.000248	0.000844	CcSEcCtD
Tacrolimus—Cardiac arrest—Prednisone—Crohn's disease	0.000247	0.000843	CcSEcCtD
Tacrolimus—Dry mouth—Mesalazine—Crohn's disease	0.000247	0.00084	CcSEcCtD
Tacrolimus—Mood swings—Prednisone—Crohn's disease	0.000247	0.000839	CcSEcCtD
Tacrolimus—Confusional state—Mesalazine—Crohn's disease	0.000244	0.00083	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000242	0.000823	CcSEcCtD
Tacrolimus—Oedema—Mesalazine—Crohn's disease	0.000242	0.000823	CcSEcCtD
Tacrolimus—Anaphylactic shock—Mesalazine—Crohn's disease	0.000242	0.000823	CcSEcCtD
Tacrolimus—Infection—Mesalazine—Crohn's disease	0.00024	0.000818	CcSEcCtD
Tacrolimus—Dry skin—Prednisone—Crohn's disease	0.000239	0.000812	CcSEcCtD
Tacrolimus—Shock—Mesalazine—Crohn's disease	0.000238	0.00081	CcSEcCtD
Tacrolimus—Nervous system disorder—Mesalazine—Crohn's disease	0.000237	0.000807	CcSEcCtD
Tacrolimus—Hypokalaemia—Prednisone—Crohn's disease	0.000237	0.000806	CcSEcCtD
Tacrolimus—Thrombocytopenia—Mesalazine—Crohn's disease	0.000237	0.000806	CcSEcCtD
Tacrolimus—Tachycardia—Mesalazine—Crohn's disease	0.000236	0.000803	CcSEcCtD
Tacrolimus—Skin disorder—Mesalazine—Crohn's disease	0.000235	0.0008	CcSEcCtD
Tacrolimus—Hyperhidrosis—Mesalazine—Crohn's disease	0.000234	0.000796	CcSEcCtD
Tacrolimus—Anorexia—Mesalazine—Crohn's disease	0.00023	0.000785	CcSEcCtD
Tacrolimus—Muscular weakness—Prednisone—Crohn's disease	0.00023	0.000782	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000229	0.00078	CcSEcCtD
Tacrolimus—Abdominal distension—Prednisone—Crohn's disease	0.000226	0.000771	CcSEcCtD
Tacrolimus—Hypotension—Mesalazine—Crohn's disease	0.000226	0.000769	CcSEcCtD
Tacrolimus—Pancreatitis—Prednisone—Crohn's disease	0.000221	0.000751	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.00022	0.00075	CcSEcCtD
Tacrolimus—Sweating increased—Prednisone—Crohn's disease	0.000219	0.000746	CcSEcCtD
Tacrolimus—Feeling abnormal—Azathioprine—Crohn's disease	0.000219	0.000745	CcSEcCtD
Tacrolimus—Insomnia—Mesalazine—Crohn's disease	0.000219	0.000744	CcSEcCtD
Tacrolimus—Paraesthesia—Mesalazine—Crohn's disease	0.000217	0.000739	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000217	0.000739	CcSEcCtD
Tacrolimus—Dyspnoea—Mesalazine—Crohn's disease	0.000216	0.000734	CcSEcCtD
Tacrolimus—Somnolence—Mesalazine—Crohn's disease	0.000215	0.000732	CcSEcCtD
Tacrolimus—Dyspepsia—Mesalazine—Crohn's disease	0.000213	0.000725	CcSEcCtD
Tacrolimus—Neutropenia—Prednisone—Crohn's disease	0.00021	0.000716	CcSEcCtD
Tacrolimus—Decreased appetite—Mesalazine—Crohn's disease	0.00021	0.000716	CcSEcCtD
Tacrolimus—Abdominal pain—Azathioprine—Crohn's disease	0.00021	0.000714	CcSEcCtD
Tacrolimus—Body temperature increased—Azathioprine—Crohn's disease	0.00021	0.000714	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000209	0.000711	CcSEcCtD
Tacrolimus—Fatigue—Mesalazine—Crohn's disease	0.000208	0.00071	CcSEcCtD
Tacrolimus—Pain—Mesalazine—Crohn's disease	0.000207	0.000704	CcSEcCtD
Tacrolimus—Constipation—Mesalazine—Crohn's disease	0.000207	0.000704	CcSEcCtD
Tacrolimus—Weight increased—Prednisone—Crohn's disease	0.000205	0.000697	CcSEcCtD
Tacrolimus—Weight decreased—Prednisone—Crohn's disease	0.000204	0.000693	CcSEcCtD
Tacrolimus—Hyperglycaemia—Prednisone—Crohn's disease	0.000203	0.000691	CcSEcCtD
Tacrolimus—Depression—Prednisone—Crohn's disease	0.0002	0.000681	CcSEcCtD
Tacrolimus—Feeling abnormal—Mesalazine—Crohn's disease	0.000199	0.000678	CcSEcCtD
Tacrolimus—Acute coronary syndrome—Prednisone—Crohn's disease	0.000198	0.000673	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000198	0.000673	CcSEcCtD
Tacrolimus—Myocardial infarction—Prednisone—Crohn's disease	0.000197	0.000669	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Prednisone—Crohn's disease	0.000197	0.000669	CcSEcCtD
Tacrolimus—Hypersensitivity—Azathioprine—Crohn's disease	0.000196	0.000666	CcSEcCtD
Tacrolimus—Urticaria—Mesalazine—Crohn's disease	0.000192	0.000654	CcSEcCtD
Tacrolimus—Body temperature increased—Mesalazine—Crohn's disease	0.000191	0.000651	CcSEcCtD
Tacrolimus—Abdominal pain—Mesalazine—Crohn's disease	0.000191	0.000651	CcSEcCtD
Tacrolimus—Bradycardia—Prednisone—Crohn's disease	0.000183	0.000624	CcSEcCtD
Tacrolimus—Diarrhoea—Azathioprine—Crohn's disease	0.000182	0.000618	CcSEcCtD
Tacrolimus—Haemoglobin—Prednisone—Crohn's disease	0.000181	0.000616	CcSEcCtD
Tacrolimus—Haemorrhage—Prednisone—Crohn's disease	0.00018	0.000613	CcSEcCtD
Tacrolimus—Hallucination—Prednisone—Crohn's disease	0.000179	0.00061	CcSEcCtD
Tacrolimus—Hypersensitivity—Mesalazine—Crohn's disease	0.000178	0.000606	CcSEcCtD
Tacrolimus—Connective tissue disorder—Prednisone—Crohn's disease	0.000177	0.000602	CcSEcCtD
Tacrolimus—Dizziness—Azathioprine—Crohn's disease	0.000176	0.000598	CcSEcCtD
Tacrolimus—Asthenia—Mesalazine—Crohn's disease	0.000173	0.000591	CcSEcCtD
Tacrolimus—Pruritus—Mesalazine—Crohn's disease	0.000171	0.000582	CcSEcCtD
Tacrolimus—Vomiting—Azathioprine—Crohn's disease	0.000169	0.000575	CcSEcCtD
Tacrolimus—Eye disorder—Prednisone—Crohn's disease	0.000168	0.000573	CcSEcCtD
Tacrolimus—Rash—Azathioprine—Crohn's disease	0.000167	0.00057	CcSEcCtD
Tacrolimus—Dermatitis—Azathioprine—Crohn's disease	0.000167	0.000569	CcSEcCtD
Tacrolimus—Flushing—Prednisone—Crohn's disease	0.000167	0.000569	CcSEcCtD
Tacrolimus—Headache—Azathioprine—Crohn's disease	0.000166	0.000566	CcSEcCtD
Tacrolimus—Diarrhoea—Mesalazine—Crohn's disease	0.000165	0.000563	CcSEcCtD
Tacrolimus—Angiopathy—Prednisone—Crohn's disease	0.000163	0.000556	CcSEcCtD
Tacrolimus—Immune system disorder—Prednisone—Crohn's disease	0.000163	0.000554	CcSEcCtD
Tacrolimus—Arrhythmia—Prednisone—Crohn's disease	0.000161	0.000548	CcSEcCtD
Tacrolimus—Dizziness—Mesalazine—Crohn's disease	0.00016	0.000544	CcSEcCtD
Tacrolimus—Alopecia—Prednisone—Crohn's disease	0.000159	0.000542	CcSEcCtD
Tacrolimus—Mental disorder—Prednisone—Crohn's disease	0.000158	0.000537	CcSEcCtD
Tacrolimus—Nausea—Azathioprine—Crohn's disease	0.000158	0.000537	CcSEcCtD
Tacrolimus—Erythema—Prednisone—Crohn's disease	0.000157	0.000534	CcSEcCtD
Tacrolimus—Malnutrition—Prednisone—Crohn's disease	0.000157	0.000534	CcSEcCtD
Tacrolimus—Vomiting—Mesalazine—Crohn's disease	0.000154	0.000523	CcSEcCtD
Tacrolimus—Rash—Mesalazine—Crohn's disease	0.000152	0.000519	CcSEcCtD
Tacrolimus—Dermatitis—Mesalazine—Crohn's disease	0.000152	0.000519	CcSEcCtD
Tacrolimus—Headache—Mesalazine—Crohn's disease	0.000151	0.000516	CcSEcCtD
Tacrolimus—Vision blurred—Prednisone—Crohn's disease	0.000148	0.000503	CcSEcCtD
Tacrolimus—Ill-defined disorder—Prednisone—Crohn's disease	0.000145	0.000495	CcSEcCtD
Tacrolimus—Anaemia—Prednisone—Crohn's disease	0.000145	0.000493	CcSEcCtD
Tacrolimus—Agitation—Prednisone—Crohn's disease	0.000144	0.00049	CcSEcCtD
Tacrolimus—Nausea—Mesalazine—Crohn's disease	0.000144	0.000489	CcSEcCtD
Tacrolimus—Malaise—Prednisone—Crohn's disease	0.000141	0.000481	CcSEcCtD
Tacrolimus—Vertigo—Prednisone—Crohn's disease	0.000141	0.000479	CcSEcCtD
Tacrolimus—Syncope—Prednisone—Crohn's disease	0.000141	0.000479	CcSEcCtD
Tacrolimus—Loss of consciousness—Prednisone—Crohn's disease	0.000138	0.000469	CcSEcCtD
Tacrolimus—Convulsion—Prednisone—Crohn's disease	0.000136	0.000462	CcSEcCtD
Tacrolimus—Hypertension—Prednisone—Crohn's disease	0.000135	0.000461	CcSEcCtD
Tacrolimus—Myalgia—Prednisone—Crohn's disease	0.000133	0.000454	CcSEcCtD
Tacrolimus—Arthralgia—Prednisone—Crohn's disease	0.000133	0.000454	CcSEcCtD
Tacrolimus—Anxiety—Prednisone—Crohn's disease	0.000133	0.000453	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000133	0.000451	CcSEcCtD
Tacrolimus—Discomfort—Prednisone—Crohn's disease	0.000132	0.000449	CcSEcCtD
Tacrolimus—Anaphylactic shock—Prednisone—Crohn's disease	0.000128	0.000436	CcSEcCtD
Tacrolimus—Oedema—Prednisone—Crohn's disease	0.000128	0.000436	CcSEcCtD
Tacrolimus—Infection—Prednisone—Crohn's disease	0.000127	0.000433	CcSEcCtD
Tacrolimus—Shock—Prednisone—Crohn's disease	0.000126	0.000428	CcSEcCtD
Tacrolimus—Nervous system disorder—Prednisone—Crohn's disease	0.000125	0.000427	CcSEcCtD
Tacrolimus—Tachycardia—Prednisone—Crohn's disease	0.000125	0.000425	CcSEcCtD
Tacrolimus—Skin disorder—Prednisone—Crohn's disease	0.000124	0.000423	CcSEcCtD
Tacrolimus—Hyperhidrosis—Prednisone—Crohn's disease	0.000124	0.000421	CcSEcCtD
Tacrolimus—Anorexia—Prednisone—Crohn's disease	0.000122	0.000415	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000117	0.000397	CcSEcCtD
Tacrolimus—Insomnia—Prednisone—Crohn's disease	0.000116	0.000394	CcSEcCtD
Tacrolimus—Paraesthesia—Prednisone—Crohn's disease	0.000115	0.000391	CcSEcCtD
Tacrolimus—Dyspepsia—Prednisone—Crohn's disease	0.000113	0.000383	CcSEcCtD
Tacrolimus—Decreased appetite—Prednisone—Crohn's disease	0.000111	0.000379	CcSEcCtD
Tacrolimus—Fatigue—Prednisone—Crohn's disease	0.00011	0.000375	CcSEcCtD
Tacrolimus—Constipation—Prednisone—Crohn's disease	0.000109	0.000372	CcSEcCtD
Tacrolimus—Feeling abnormal—Prednisone—Crohn's disease	0.000105	0.000359	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Prednisone—Crohn's disease	0.000105	0.000356	CcSEcCtD
Tacrolimus—Urticaria—Prednisone—Crohn's disease	0.000102	0.000346	CcSEcCtD
Tacrolimus—Abdominal pain—Prednisone—Crohn's disease	0.000101	0.000344	CcSEcCtD
Tacrolimus—Body temperature increased—Prednisone—Crohn's disease	0.000101	0.000344	CcSEcCtD
Tacrolimus—Hypersensitivity—Prednisone—Crohn's disease	9.42e-05	0.000321	CcSEcCtD
Tacrolimus—Asthenia—Prednisone—Crohn's disease	9.18e-05	0.000312	CcSEcCtD
Tacrolimus—Pruritus—Prednisone—Crohn's disease	9.05e-05	0.000308	CcSEcCtD
Tacrolimus—PPP3CA—Innate Immune System—JAK2—Crohn's disease	8.83e-05	0.000782	CbGpPWpGaD
Tacrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—Crohn's disease	8.81e-05	0.00078	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—JAK2—Crohn's disease	8.78e-05	0.000778	CbGpPWpGaD
Tacrolimus—Diarrhoea—Prednisone—Crohn's disease	8.75e-05	0.000298	CcSEcCtD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	8.73e-05	0.000773	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	8.73e-05	0.000773	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—STAT3—Crohn's disease	8.73e-05	0.000773	CbGpPWpGaD
Tacrolimus—MTOR—Disease—LTF—Crohn's disease	8.68e-05	0.000769	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—IL3—Crohn's disease	8.66e-05	0.000767	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—UBE2D1—Crohn's disease	8.65e-05	0.000766	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL18—Crohn's disease	8.62e-05	0.000763	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—STAT3—Crohn's disease	8.58e-05	0.00076	CbGpPWpGaD
Tacrolimus—MTOR—Insulin receptor signalling cascade—IL6—Crohn's disease	8.58e-05	0.00076	CbGpPWpGaD
Tacrolimus—MTOR—IGF1R signaling cascade—IL6—Crohn's disease	8.58e-05	0.00076	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	8.53e-05	0.000755	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—RBX1—Crohn's disease	8.52e-05	0.000755	CbGpPWpGaD
Tacrolimus—Dizziness—Prednisone—Crohn's disease	8.46e-05	0.000288	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—RIPK2—Crohn's disease	8.39e-05	0.000743	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—RASGRP1—Crohn's disease	8.38e-05	0.000742	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—IL2RA—Crohn's disease	8.38e-05	0.000742	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—TNF—Crohn's disease	8.37e-05	0.000742	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—CD4—Crohn's disease	8.37e-05	0.000742	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—IFNG—Crohn's disease	8.36e-05	0.000741	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—UBE2D1—Crohn's disease	8.31e-05	0.000736	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PTGER4—Crohn's disease	8.29e-05	0.000735	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—UBE2D1—Crohn's disease	8.27e-05	0.000733	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TAGAP—Crohn's disease	8.18e-05	0.000725	CbGpPWpGaD
Tacrolimus—Vomiting—Prednisone—Crohn's disease	8.13e-05	0.000277	CcSEcCtD
Tacrolimus—Rash—Prednisone—Crohn's disease	8.07e-05	0.000275	CcSEcCtD
Tacrolimus—Dermatitis—Prednisone—Crohn's disease	8.06e-05	0.000274	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—RIPK2—Crohn's disease	8.06e-05	0.000713	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—ITGA4—Crohn's disease	8.06e-05	0.000713	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—PTGS2—Crohn's disease	8.02e-05	0.00071	CbGpPWpGaD
Tacrolimus—Headache—Prednisone—Crohn's disease	8.01e-05	0.000273	CcSEcCtD
Tacrolimus—ABCB1—Allograft Rejection—IFNG—Crohn's disease	7.99e-05	0.000707	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—RASGRP1—Crohn's disease	7.91e-05	0.000701	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—STAT3—Crohn's disease	7.85e-05	0.000695	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—Crohn's disease	7.81e-05	0.000692	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—TAB1—Crohn's disease	7.74e-05	0.000686	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PLA2G4F—Crohn's disease	7.72e-05	0.000684	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—Crohn's disease	7.72e-05	0.000684	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL2RA—Crohn's disease	7.65e-05	0.000678	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	7.65e-05	0.000677	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	7.65e-05	0.000677	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—SMAD3—Crohn's disease	7.63e-05	0.000676	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—NOD2—Crohn's disease	7.61e-05	0.000674	CbGpPWpGaD
Tacrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—Crohn's disease	7.6e-05	0.000673	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—RASGRP1—Crohn's disease	7.6e-05	0.000673	CbGpPWpGaD
Tacrolimus—Nausea—Prednisone—Crohn's disease	7.6e-05	0.000259	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—CD79A—Crohn's disease	7.57e-05	0.000671	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—UBE2D1—Crohn's disease	7.47e-05	0.000662	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—IL1B—Crohn's disease	7.46e-05	0.000661	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—F5—Crohn's disease	7.45e-05	0.00066	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—CXCL8—Crohn's disease	7.43e-05	0.000658	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCR6—Crohn's disease	7.3e-05	0.000647	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—STAT3—Crohn's disease	7.28e-05	0.000644	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—RIPK2—Crohn's disease	7.24e-05	0.000642	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CRP—Crohn's disease	7.22e-05	0.000639	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—IL6—Crohn's disease	7.18e-05	0.000636	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—SOCS1—Crohn's disease	7.17e-05	0.000635	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RSPO3—Crohn's disease	7.15e-05	0.000633	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	7.15e-05	0.000633	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by Insulin receptor—IL6—Crohn's disease	7.13e-05	0.000631	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL1B—Crohn's disease	7.12e-05	0.000631	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—STAT3—Crohn's disease	7.12e-05	0.00063	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—TYK2—Crohn's disease	7.08e-05	0.000627	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL3—Crohn's disease	7.06e-05	0.000626	CbGpPWpGaD
Tacrolimus—MTOR—Disease—GCKR—Crohn's disease	7e-05	0.00062	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NOD1—Crohn's disease	7e-05	0.00062	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—TLR4—Crohn's disease	6.92e-05	0.000613	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—SOCS1—Crohn's disease	6.88e-05	0.00061	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—RASGRP1—Crohn's disease	6.83e-05	0.000605	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—TNF—Crohn's disease	6.81e-05	0.000603	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SEL1L—Crohn's disease	6.78e-05	0.000601	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—IL6—Crohn's disease	6.76e-05	0.000598	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—JAK2—Crohn's disease	6.75e-05	0.000598	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	6.7e-05	0.000593	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—ICAM1—Crohn's disease	6.64e-05	0.000588	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RBX1—Crohn's disease	6.61e-05	0.000585	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—CXCL8—Crohn's disease	6.57e-05	0.000582	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—MTMR3—Crohn's disease	6.57e-05	0.000582	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—Crohn's disease	6.44e-05	0.000571	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PTGER4—Crohn's disease	6.43e-05	0.00057	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CCR6—Crohn's disease	6.35e-05	0.000563	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCR9—Crohn's disease	6.2e-05	0.000549	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—SOCS1—Crohn's disease	6.19e-05	0.000548	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SLC11A1—Crohn's disease	6.19e-05	0.000548	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—GCKR—Crohn's disease	6.15e-05	0.000545	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—IL6—Crohn's disease	6.1e-05	0.00054	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	6.07e-05	0.000537	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—SMAD3—Crohn's disease	5.92e-05	0.000524	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—TYK2—Crohn's disease	5.9e-05	0.000523	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—IL6—Crohn's disease	5.83e-05	0.000517	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PTPN2—Crohn's disease	5.81e-05	0.000515	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—UBE2D1—Crohn's disease	5.79e-05	0.000513	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—GPR65—Crohn's disease	5.77e-05	0.000511	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—RBX1—Crohn's disease	5.75e-05	0.000509	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—IL6—Crohn's disease	5.74e-05	0.000508	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—JAK2—Crohn's disease	5.63e-05	0.000499	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RIPK2—Crohn's disease	5.62e-05	0.000497	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PLA2G4F—Crohn's disease	5.58e-05	0.000495	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—IL6—Crohn's disease	5.5e-05	0.000487	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—IL6—Crohn's disease	5.48e-05	0.000486	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL3—Crohn's disease	5.48e-05	0.000485	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—IL6—Crohn's disease	5.46e-05	0.000483	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	5.44e-05	0.000482	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—IL6—Crohn's disease	5.43e-05	0.000481	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—TNF—Crohn's disease	5.41e-05	0.000479	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CRP—Crohn's disease	5.41e-05	0.000479	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—IL6—Crohn's disease	5.4e-05	0.000478	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—TYK2—Crohn's disease	5.39e-05	0.000478	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—GCKR—Crohn's disease	5.39e-05	0.000477	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—SMAD3—Crohn's disease	5.34e-05	0.000473	CbGpPWpGaD
Tacrolimus—MTOR—Disease—RBX1—Crohn's disease	5.31e-05	0.00047	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HSPA1B—Crohn's disease	5.31e-05	0.00047	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RASGRP1—Crohn's disease	5.3e-05	0.000469	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—STAT3—Crohn's disease	5.28e-05	0.000468	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—TLR4—Crohn's disease	5.18e-05	0.000459	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—TNF—Crohn's disease	5.17e-05	0.000458	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—JAK2—Crohn's disease	5.14e-05	0.000456	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—CXCL8—Crohn's disease	5.14e-05	0.000455	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—FADS1—Crohn's disease	5.12e-05	0.000453	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—Crohn's disease	5.08e-05	0.00045	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—IL6—Crohn's disease	5.08e-05	0.00045	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—IL6—Crohn's disease	5.08e-05	0.00045	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IFNG—Crohn's disease	5.05e-05	0.000447	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—UBE2D1—Crohn's disease	5.04e-05	0.000446	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—IL6—Crohn's disease	5.04e-05	0.000446	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—IL6—Crohn's disease	4.99e-05	0.000442	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—TYK2—Crohn's disease	4.98e-05	0.000441	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—IL6—Crohn's disease	4.97e-05	0.00044	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—STAT3—Crohn's disease	4.96e-05	0.000439	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL2RA—Crohn's disease	4.95e-05	0.000438	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—RIPK2—Crohn's disease	4.89e-05	0.000433	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ITGA4—Crohn's disease	4.89e-05	0.000433	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD4—Crohn's disease	4.88e-05	0.000432	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PLA2G4F—Crohn's disease	4.81e-05	0.000426	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SOCS1—Crohn's disease	4.8e-05	0.000425	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GPX4—Crohn's disease	4.79e-05	0.000424	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—ICAM1—Crohn's disease	4.77e-05	0.000423	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL3—Crohn's disease	4.76e-05	0.000422	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	4.76e-05	0.000422	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—JAK2—Crohn's disease	4.75e-05	0.000421	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—MTMR3—Crohn's disease	4.75e-05	0.00042	CbGpPWpGaD
Tacrolimus—MTOR—Disease—UBE2D1—Crohn's disease	4.65e-05	0.000412	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GCKR—Crohn's disease	4.63e-05	0.00041	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—RASGRP1—Crohn's disease	4.61e-05	0.000408	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD79A—Crohn's disease	4.59e-05	0.000407	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—ITGA4—Crohn's disease	4.58e-05	0.000405	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—IL6—Crohn's disease	4.53e-05	0.000401	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—TAB1—Crohn's disease	4.51e-05	0.000399	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL1B—Crohn's disease	4.5e-05	0.000399	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CD4—Crohn's disease	4.5e-05	0.000399	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—Crohn's disease	4.5e-05	0.000399	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PTGS2—Crohn's disease	4.47e-05	0.000396	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL3—Crohn's disease	4.46e-05	0.000395	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NOD2—Crohn's disease	4.43e-05	0.000392	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—IL6—Crohn's disease	4.37e-05	0.000387	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—RASGRP1—Crohn's disease	4.32e-05	0.000382	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PLA2G4F—Crohn's disease	4.21e-05	0.000373	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—SOCS1—Crohn's disease	4.18e-05	0.00037	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SMAD3—Crohn's disease	4.14e-05	0.000367	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCR6—Crohn's disease	4.11e-05	0.000364	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—MTMR3—Crohn's disease	4.09e-05	0.000362	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	4.08e-05	0.000361	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—TYK2—Crohn's disease	4.04e-05	0.000358	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—TYK2—Crohn's disease	3.86e-05	0.000342	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—JAK2—Crohn's disease	3.85e-05	0.000341	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL2RA—Crohn's disease	3.84e-05	0.00034	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	3.78e-05	0.000335	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—STAT3—Crohn's disease	3.78e-05	0.000334	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL18—Crohn's disease	3.76e-05	0.000333	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RBX1—Crohn's disease	3.72e-05	0.000329	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—FADS1—Crohn's disease	3.7e-05	0.000328	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—IL6—Crohn's disease	3.69e-05	0.000327	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—JAK2—Crohn's disease	3.68e-05	0.000326	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CD4—Crohn's disease	3.65e-05	0.000323	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTGER4—Crohn's disease	3.62e-05	0.00032	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—MTMR3—Crohn's disease	3.58e-05	0.000317	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD4—Crohn's disease	3.51e-05	0.000311	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CD4—Crohn's disease	3.49e-05	0.000309	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TYK2—Crohn's disease	3.49e-05	0.000309	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—STAT3—Crohn's disease	3.49e-05	0.000309	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTGS2—Crohn's disease	3.47e-05	0.000307	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GPX4—Crohn's disease	3.46e-05	0.000307	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—IL6—Crohn's disease	3.46e-05	0.000307	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GCKR—Crohn's disease	3.34e-05	0.000296	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL2RA—Crohn's disease	3.34e-05	0.000296	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SMAD3—Crohn's disease	3.33e-05	0.000295	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—JAK2—Crohn's disease	3.33e-05	0.000295	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—UBE2D1—Crohn's disease	3.26e-05	0.000289	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—FADS1—Crohn's disease	3.19e-05	0.000282	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RIPK2—Crohn's disease	3.16e-05	0.00028	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CRP—Crohn's disease	3.15e-05	0.000279	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2RA—Crohn's disease	3.13e-05	0.000277	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL3—Crohn's disease	3.08e-05	0.000273	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CXCL8—Crohn's disease	3.04e-05	0.000269	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—TLR4—Crohn's disease	3.02e-05	0.000267	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GPX4—Crohn's disease	2.98e-05	0.000264	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RASGRP1—Crohn's disease	2.98e-05	0.000264	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ICAM1—Crohn's disease	2.89e-05	0.000256	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—IL6—Crohn's disease	2.89e-05	0.000256	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GCKR—Crohn's disease	2.88e-05	0.000255	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—FADS1—Crohn's disease	2.79e-05	0.000247	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TYK2—Crohn's disease	2.7e-05	0.000239	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—STAT3—Crohn's disease	2.7e-05	0.000239	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SOCS1—Crohn's disease	2.7e-05	0.000239	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL6—Crohn's disease	2.64e-05	0.000234	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GPX4—Crohn's disease	2.61e-05	0.000231	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	2.6e-05	0.00023	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—JAK2—Crohn's disease	2.58e-05	0.000228	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	2.55e-05	0.000226	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GCKR—Crohn's disease	2.52e-05	0.000224	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—STAT3—Crohn's disease	2.44e-05	0.000216	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—IL6—Crohn's disease	2.44e-05	0.000216	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CXCL8—Crohn's disease	2.35e-05	0.000208	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—TYK2—Crohn's disease	2.35e-05	0.000208	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SMAD3—Crohn's disease	2.33e-05	0.000206	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—JAK2—Crohn's disease	2.24e-05	0.000199	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MTMR3—Crohn's disease	2.21e-05	0.000195	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IFNG—Crohn's disease	2.2e-05	0.000195	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TYK2—Crohn's disease	2.17e-05	0.000192	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2RA—Crohn's disease	2.16e-05	0.000191	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD4—Crohn's disease	2.13e-05	0.000188	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—JAK2—Crohn's disease	2.1e-05	0.000186	CbGpPWpGaD
Tacrolimus—MTOR—Disease—JAK2—Crohn's disease	2.07e-05	0.000183	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—IL6—Crohn's disease	1.97e-05	0.000175	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL1B—Crohn's disease	1.96e-05	0.000174	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CD4—Crohn's disease	1.96e-05	0.000174	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—Crohn's disease	1.95e-05	0.000173	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—STAT3—Crohn's disease	1.89e-05	0.000168	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—IL6—Crohn's disease	1.89e-05	0.000167	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.8e-05	0.00016	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—FADS1—Crohn's disease	1.72e-05	0.000152	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	1.72e-05	0.000152	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL6—Crohn's disease	1.71e-05	0.000151	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—STAT3—Crohn's disease	1.65e-05	0.000146	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GPX4—Crohn's disease	1.61e-05	0.000143	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GCKR—Crohn's disease	1.56e-05	0.000138	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TYK2—Crohn's disease	1.52e-05	0.000135	CbGpPWpGaD
Tacrolimus—MTOR—Disease—STAT3—Crohn's disease	1.52e-05	0.000135	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ALB—Crohn's disease	1.47e-05	0.00013	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—JAK2—Crohn's disease	1.45e-05	0.000128	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL8—Crohn's disease	1.32e-05	0.000117	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL6—Crohn's disease	1.32e-05	0.000117	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—Crohn's disease	1.29e-05	0.000114	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL6—Crohn's disease	1.15e-05	0.000102	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STAT3—Crohn's disease	1.06e-05	9.43e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ALB—Crohn's disease	1.06e-05	9.43e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—IL6—Crohn's disease	1.06e-05	9.41e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—Crohn's disease	9.31e-06	8.25e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALB—Crohn's disease	8.03e-06	7.11e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—Crohn's disease	8.02e-06	7.1e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL6—Crohn's disease	7.44e-06	6.59e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—Crohn's disease	7.03e-06	6.22e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALB—Crohn's disease	4.95e-06	4.38e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—Crohn's disease	4.33e-06	3.83e-05	CbGpPWpGaD
